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Background: Hypermethylation of the promoter of the tumor suppressor gene RASSF1A silences its expression and
has been found to be associated with advanced grade prostatic tumors. The DNA methyltransferase (DNMT) family
of enzymes are known to be involved in the epigenetic silencing of gene expression, including RASSF1A, and are
often overexpressed in prostate cancer. The present study demonstrates how mahanine, a plant-derived carbazole
alkaloid, restores RASSF1A expression by down-regulating specific members of the DNMT family of proteins in
prostate cancer cells.
Results: Using methylation-specific PCR we establish that mahanine restores the expression of RASSF1A by inducing
the demethylation of its promoter in prostate cancer cells. Furthermore, we show that mahanine treatment induces
the degradation of DNMT1 and DNMT3B, but not DNMT3A, via the ubiquitin-proteasome pathway; an effect which
is rescued in the presence of a proteasome inhibitor, MG132. The inactivation of Akt by wortmannin, a PI3K
inhibitor, results in a similar down-regulation in the levels DNMT1 and DNMT3B. Mahanine treatment results in a
decline in phospho-Akt levels and a disruption in the interaction of Akt with DNMT1 and DNMT3B. Conversely, the
exogenous expression of constitutively active Akt inhibits the ability of mahanine to down-regulate these DNMTs,
suggesting that the degradation of DNMT1 and DNMT3B by mahanine occurs via Akt inactivation.
Conclusions: Taken together, we show that mahanine treatment induces the proteasomal degradation of DNMT1
and DNMT3B via the inactivation of Akt, which facilitates the demethylation of the RASSF1A promoter and restores
its expression in prostate cancer cells. Therefore, mahanine could be a potential therapeutic agent for advanced
prostate cancer in men when RASSF1A expression is silenced.
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Prostate cancer is the most common non-cutaneous
malignancy in men in the Western world. The etiology
of prostate cancer is not well defined; however, the
inhibition of various tumor suppressor genes and con-
comitant activation of oncogenes is a frequent occur-
rence in most cancers, including prostate cancer. DNA
hypermethylation of promoters at CpG sequences often
sterically hinders the binding of transcription factors,* Correspondence: ppb@georgetown.edu
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reproduction in any medium, provided the orthereby represses gene transcription [1]. The transfer of
a methyl group to DNA at the fifth carbon position of
cytosine residues by the DNA methyltransferase (DNMT)
family of enzymes is one of the most common events
for the establishment of epigenetic program [2]. Three
active DNMTs have been identified so far in mammalian
cells; DNMT1 (Gene ID: 1786), DNMT3A (Gene ID:
1788), and DNMT3B (Gene ID: 1789). DNMT1 is the
most abundant and methylates hemimethylated CpG
di-nucleotides in the mammalian genome during DNA
replication in a number of different cancer types [3].
DNMT3A and DNMT3B are methyltransferases involved
in de novo methylation of DNA following replication [4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sion of DNMT1 in lung, hepatocellular, acute and chronic
myelogenous leukemia, colorectal, gastric, breast and
prostate cancers [5-11]. Gravina and associates have
shown that the hormone resistant prostate cancer
phenotype is associated with an increase in DNMT
expression and activity [12]. The majority of gene silen-
cing induced by DNA hypermethylation in prostate
cancer can be attributed to DNMT activity [13]. Since
promoter hypermethylation results in the silencing of
several tumor suppressor genes in cancer cells, the
reactivation of these genes by demethylation of their
promoters is a feasible approach to cancer therapy. DNMT
inhibitors, such as 5-aza-deoxycytidine and 5-aza-2’-
deoxycitidine, have been used extensively in clinical
trials for cancer treatment. These nucleoside analogues
bind covalently to the DNMTs and irreversibly inhibit
their function, leading to the demethylation of silenced
promoters and subsequently, the activation of gene
expression. However, studies in rodent cell lines and
bacteria have indicated that these azacitidine-DNMT
adducts are toxic and mutagenic if not repaired [14-16].
In addition, these compounds are unstable in neutral
aqueous solution and disintegrate to yield more stable
analogues such as 5, 6-dihydro-5-azacytidine and 5-
fluoro-2’-deoxycytidine [17], that have been shown to
have toxicity related issues in clinical trials [18,19].
Therefore, there is an urgent need for the development
of new drugs that will target DNMT with low toxicity.
Ras-association domain family 1A (RASSF1A; Gene ID:
11186) gene has been found to be the most frequently
methylated gene described thus far in human cancers
[20,21]. Hypermethylation of the promoter of RASSF1A
gene at its CpG-island has been observed in 70% of
prostate cancers [22,23]. Since the restoration of RASSF1A
expression in tumor cell lines impairs tumorigenicity
[22,24], factors that restore RASSF1A expression have
immense importance in preventing tumor growth. We
demonstrated earlier that mahanine induces RASSF1A
gene expression in a diverse range of cancer cell types,
including epidermoid, lung, pancreatic, colon, breast,
ovarian and prostate cancer cells [25]. Although we
showed a decline in DNMT activity upon mahanine
treatment, the scope of our study did not include
establishing a causative effect of DNMT inhibition on
RASSF1A re-expression by mahanine, and this mechanism
remains to be explored.
The cellular levels of DNMTs in mammalian cells can
be regulated by transcriptional events or posttranslational
modifications of enzymes which ultimately affect the
catalytic activity and degradation of the DNMT proteins
[26]. DNMT1 is known to be phosphorylated at several
serine and threonine residues under physiological
conditions. Sun and associates have reported that Aktenhances DNMT1 protein stability by inhibition of its
ubiquitin–proteasome mediated degradation [27]. Re-
cently it has been demonstrated that Akt1 directly
interacts and phosphorylates Ser143 of DNMT1 to
increase its stability [28].
In the present study, we sought to establish the mechan-
ism by which mahanine inactivates DNMTs and thereby
restores RASSF1A expression in prostate cancer cells.
We show that mahanine induces the degradation of
DNMT1 and DNMT3B via the ubiquitin-proteasome
mediated pathway in both androgen-responsive LNCaP
and androgen receptor-negative PC3 human prostate
cancer cells. Interestingly, our data suggests that the
inactivation of Akt by mahanine treatment is involved
in inducing DNMT degradation, thereby restoring the
expression of the epigenetically silenced tumor suppressor
gene RASSF1A.
Results
Mahanine demethylates RASSF1A promoter and restores
its expression in prostate cancer cells
Our prior work demonstrated the ability of mahanine
to restore RASSF1A expression in various cancer cell
lines, including prostate cancer [25]. To further explore
this finding, we analyzed the methylation pattern of the
RASSF1A promoter using methylation-specific PCR in
PC3 and LNCaP cells treated with mahanine for a
period of 24 and 72 hours. Expectedly, we observed
high amounts of methylated RASSF1A promoter in un-
treated PC3 and LNCaP cells, confirming that RASSF1A
expression is silenced in prostate cancer cells. However,
after 24 hours of mahanine treatment, there was a notice-
able increase in the levels of unmethylated RASSF1A
promoter compared to control; and after 72 hours, this
effect was even more dramatic, with higher amounts of
unmethylated RASSF1A promoter than methylated in
the mahanine-treated cells (Figure 1A and Additional
file 1: Figure S1A). In order to confirm that the observed
decrease in methylation of the RASSF1A promoter
upon mahanine treatment results in the restoration of
its expression in cells, we treated PC3 cells with mahanine
for 72 hours and checked the message levels of RASSF1A
by RT-PCR. The detectable expression of RASSF1A
after mahanine treatment for 72 hours, but not 24
hours (Figure 1B), correlates well with our PCR data,
and confirms the ability of mahanine to restore RASSF1A
expression by decreasing the methylation of its promoter
in prostate cancer cells.
All three DNMTs possess the ability to silence
RASSF1A expression
The over-expression DNMTs and the silencing of
RASSF1A expression by hypermethylation of its promoter
in prostate cancer have been well documented [29]. In
Figure 1 Mahanine restores RASSF1A expression by demethylating its promoter and all three DNMTs control RASSF1A expression. A.
PC3 cells were treated with DMSO control or 10 μM mahanine for 1 and 3 days. Methylation-specific PCR was performed to detect the
methylated (M) and un-methylated (UM) status of RASSF1A promoter. B. PC3 cells were treated with DMSO control or 10 μM mahanine for 1 and
3 days, following which RASSF1A expression was assessed by RT-PCR. GAPDH was used as an internal control. C. PC3 cells were transfected with
shRNA for DNMT1, DNMT3A, DNMT3B or scrambled shRNA. Forty-eight hours after transfection, cells were harvested for RT-PCR analyses to assess
RASSF1A expression. GAPDH was used as an internal control. For DNMT3A, two shRNAs were used to confirm the result. D. BPH1 cells were
transfected with expression vectors of DNMT1, DNMT3A, DNMT3B or empty vector control. Forty-eight hours after transfection cells were
collected for RT-PCR analyses to determine RASSF1A, DNMT1, DNMT3A and DNMT3B expression levels. GAPDH was used as an internal control.
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mediating the methylation of the RASSF1A promoter in
our system, we down-regulated the expression of DNMT1,
DNMT3A and DNMT3B in PC3 cells using specific
shRNA constructs. Loss of expression of either member of
the DNMT family resulted in restoration of RASSF1A
expression; however to a lesser extent with the DNMT3A
knock-down (Figure 1C). This suggests that all three
members of the DNMT family of proteins are involved
in the silencing of RASSF1A expression, although the
degree to which each member is involved varies. Alter-
natively, we transfected BPH1 cells, in which the native
expression of DNMTs is almost undetectable, with
expression vectors of all three types of the DNMTs
(Additional file 1: Figure S1B). The exogenous expres-
sion of either member of the DNMT family completely
inhibited RASSF1A expression (Figure 1D), suggesting
that either one of the three DNMTs are capable of
silencing RASSF1A expression in prostate epithelial cells.
Mahanine decreases nuclear localization of DNMT1
and DNMT3B
Our prior work suggests that the inactivation of DNMTs
is involved in the mechanism by which mahanine in-
duces the restoration of RASSF1A expression in prostatecancer cells [25]. To understand how mahanine mediates
the inactivation of DNMTs, we evaluated the effect of
mahanine treatment on the cellular localization of the
three DNMTs by immunocytochemical staining, since
DNMTs must localize to the nucleus to carry out their
effects. Our data revealed that DNMT1 is localized
exclusively in the nucleus in DMSO-treated, control
PC3 (Figure 2A and Additional file 2: Figure S2A) and
LNCaP (data not shown) cells. After treatment with
mahanine (10μM) for 24 hours, the nuclear levels of
DNMT1 were reduced to an undetectable level (Figure 2A
and Additional file 2: Figure S2A). DNMT3B appeared
to be distributed between the nucleus and cytoplasm in
control cells; however, upon treatment with mahanine, its
nuclear levels were undetectable, with a noticeable decline
in its cytoplasmic staining as well. In comparison with DN
MT1 and DNMT3B, the cellular distribution of DNMT3A
remained mostly unchanged by mahanine treatment.
To further confirm our immunocytochemical data, PC3
cells were treated in a similar manner with mahanine for
24 hours and nuclear and cytoplasmic fractions were sepa-
rated from the treated and untreated cells. Our data con-
firmed that while mahanine decreased DNMT1 levels
from the nucleus (~2-fold), and DNMT3B levels in the
cytoplasm (~1.5-fold) and in the nucleus (~2.2-fold), it left
Figure 2 Mahanine specifically down-regulates DNMT1 and DNMT3B. A. DNMT1, DNMT3A and DNMT3B cellular localization was visualized by
immunofluorescent staining. PC3 cells were treated with DMSO (as control) or mahanine (10 μM) for 24 hours, following which they were fixed in
methanol, incubated with the indicated antibodies, stained with Alexa Fluor 488-tagged secondary antibodies and counterstained with propidium
iodide. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or
mahanine (10 μM) for 24 hours are shown (right panel). B. Cytoplasmic and nuclear fractions were separated from PC3 cells treated with DMSO or 10
μM mahanine for 24 hours. The isolated fractions were subjected to Western blot analysis to assess DNMT expression. The fold change in the
expression of the respective DNMTs as compared to the control is indicated at the bottom of each immunoblot. Nucleolin and β-actin were used as
loading controls for the nuclear and cytoplasmic fractions, respectively. C. PC3 and LNCaP cells were treated as indicated with DMSO or mahanine
following which cells were lysed and the extracts were subjected to Western blot analysis to detect DNMT1, DNMT3B and DNMT3A protein levels (left).
Quantitative estimations of the relative levels of DNMT1, DNMT3A and DNMT3B proteins were determined by densitometric measurements of
immunoblots from three independent experiments after normalization with β-actin (right). Columns, mean; bars, SEM. *p < 0.05, significantly different
from control. D. PC3 and LNCaP cells were treated with DMSO or 10 and 20 μM mahanine, respectively for 24 hours. Subsequently, cells were
harvested for RT-PCR analysis to measure DNMT1 and DNMT3B expression. GAPDH was used as an internal control.
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modulates the cellular localization and protein levels of
DNMT1 and DNMT3B, without affecting DNMT3A
(Figure 2B).
Mahanine down-regulates DNMT1 and DNMT3B, but not
DNMT3A protein levels in prostate cancer cells
To determine if mahanine affected the total cellular levels
of the DNMTs, we treated androgen receptor-negative
PC3 cells and androgen-responsive LNCaP cells with10μM and 20μM of mahanine for a period of 24 to 48
hours. We observed that while mahanine causes a dose-
and time-dependent down-regulation in the protein levels
of DNMT1 and DNMT3B in both cell lines, it has no
effect on DNMT3A protein levels, which is in agreement
with our findings from the immunocytochemical and
nuclear-cytoplasmic fractionation experiments (Figure 2C
and Additional file 2: Figure S2B).
Next, we sought to determine whether the observed
decline in DNMT1 and DNMT3B levels was due to
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treatment. We measured the message levels of these
DNMTs as an indicator of the level of their gene expres-
sion. We did not detect a noticeable change in the
message levels of DNMT1 and DNMT3B in LNCaP or
PC3 cells with 20μM and 10μM mahanine treatment,
respectively for a period of 24 hours (Figure 2D),
suggesting that the decline in DNMT1 and DNMT3B
protein levels occurs post-translationally.
Mahanine-induced depletion of DNMTs is not mediated
by caspases
In a previous publication we demonstrated that high mi-
cromolar concentration of mahanine treatment induces
apoptosis in prostate cancer cells [30]. Since activation
of caspases degrades various proteins within the cell,
we wanted to evaluate whether the decline in cellular
levels of DNMT1 and DNMT3B upon treatment with
mahanine is mediated by a caspase-dependent pathway.
To this end, we performed live/dead cell assay and
measured the caspase activity in LNCaP and PC3 cells
with various doses of mahanine for a period of 24
hours. We did not observe an induction of cell death
(Additional file 3: Figure S3A) or caspase activityFigure 3 Mahanine degrades DNMTs via the ubiquitin-proteasomal p
Z-VAD-FMK for 24 hours after which cellular protein lysates were subjected
β-actin was used as a loading control. B. Chymotrypsin-like proteasomal ac
and MG132 for 24 hours. Columns, mean; bars, SEM. *p < 0.05, significantly
with the indicated doses of mahanine for 24 hours with or without MG132
by Western blot. β-actin was used as a loading control. D. PC3 cells were t
(10 μM) for 24 hours. Cell lysates were subjected to immunoprecipitation (I
DNMT1 and DNMT3B.(Additional file 4: Figure S4A), suggesting that apoptotic
pathways had not been induced in the cells within this
time frame of mahanine treatment (although growth
was significantly arrested as noted in Additional file 5:
Figure S5). In addition, we treated PC3 cells with
mahanine (10μM) in the absence and presence of a
pan-caspase inhibitor (Z-VAD-FMK), and checked the
cellular levels of DNMT1 and DNMT3B. The inhibition
of caspases did not hinder the ability of mahanine to
cause a decline in the levels of these DNMTs, sug-
gesting that mahanine alters their levels by an alterna-
tive mechanism, without the involvement of caspases
(Figure 3A).
Mahanine degrades DNMTs via the ubiquitin-
proteasomal pathway
Our data so far eliminates the possibility that transcrip-
tional down-regulation and caspase mediated degradation
might be the mechanism by which mahanine decreases
the levels of DNMT1 and DNMT3B. Next, we sought to
determine whether mahanine mediates DNMT depletion
through the ubiquitin-proteasomal pathway. Proteasomal
degradation generally occurs via three types of enzymatic
activities; specifically, chymotrypsin-like, trypsin-like, andathway. A. PC3 cells were treated with 10 μM mahanine and 20 μM
to Western blot analysis to detect DNMT1 and DNMT3B protein levels,
tivity was measured in PC3 cells treated as indicated with mahanine
different from DMSO control. C. LNCaP and PC3 cells were treated
(5 μM). Cell lysates were analyzed for DNMT1 and DNMT3B expression
reated with MG132 (5 μM) in the absence and presence of mahanine
P) of DNMT1 or DNMT3B and immunoblotted (IB) for poly-ubiquitin,
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the rate limiting step in the proteasomal degradation
process. To this end, we measured proteasomal activation
in PC3 cells treated with mahanine in the absence and
presence of a proteasome inhibitor, MG132. We found
that while mahanine induced chymotrypsin-like protea-
somal activity, it caused a decline in the trypsin-like and
caspase-like activities of the proteasome (Figure 3B and
Additional file 4: Figure S4B).
To determine whether the induction of chymotrypsin-
like proteasome activity by mahanine could account for
the decline in DNMT levels, PC3 and LNCaP cells were
treated with 10μM and 20μM mahanine, respectively for
24 hours in the presence and absence of MG132 (5 μM).
While mahanine treatment resulted in a decline in the
levels of DNMT1 and DNMT3B in both cell lines, this
effect was rescued upon inhibition of the proteasome,
suggesting that mahanine causes DNMT degradation via
a chymotrypsin-like proteasomal mechanism (Figure 3C).
Since proteasomal degradation is preceded by ubiqui-
tination, we immuno-precipitated DNMT1 and DNMT3B
from PC3 cells that had been treated with mahanine
and MG132, and found an increase in the levels of
ubiquitinated DNMTs in the presence of mahanine
(Figure 3D). Similarly, in mahanine-treated PC3 cells we
observed an increase in total ubiquitination (Additional
file 4: Figure S4C). Taken together, our data suggest that
mahanine decreases the cellular levels of DNMT1 and
DNMT3B by a ubiquitin-proteasome mediated pathway.
Mahanine down-regulates pAkt levels in PC3 and
LNCaP cells
The high activity of the survival kinase Akt in prostate
cancer cells is well documented [31,32]. Our previous
work has established the ability of mahanine to inactivate
Akt signalling in prostate cancer cells, thereby inhibiting
its down-stream effects like cellular proliferation and
survival [30]. Akt phosphorylation has been found to
be one of the major factors responsible for DNMT1
stabilization [33]. To evaluate whether Akt inhibition
was involved in DNMT inactivation and degradation
brought about by mahanine, we first measured the
levels of activated Akt in whole cell lysates of PC3 and
LNCaP cells treated with or without mahanine. Expect-
edly, mahanine treatment decreased phospho-Akt levels in
both, PC3 and LNCaP cells, without affecting total Akt
expression (Figure 4A), thereby confirming our previous
findings.
PI3K inhibitor, wortmannin degrades DNMT1 and DNMT3B
proteins in prostate cancer cells
Phosphoinositide 3-kinase or PI3K is an enzyme which
acts directly upstream of Akt and is essential for its ac-
tivation. To understand the relationship between Aktactivation and the stability of DNMTs in prostate cancer
cells, PC3 and LNCaP cells were treated with a PI3K
inhibitor, wortmannin for 24 hours. As expected, inhib-
ition of PI3K by wortmannin reduced phospho-Akt
levels significantly after 24 hours of treatment. Further-
more, the inactivation of Akt was accompanied by a
significant down-regulation in DNMT1 protein levels both
in PC3 (~ 2-fold) and LNCaP (~ 5-fold) cells (Figure 4B
and Additional file 6: Figure S6). A similar trend was
observed in the case of DNMT3B, with an approximate
40% and 60% reduction in its levels in PC3 and LNCaP
cells, respectively. The decrease in the levels of DNMT1
and DNMT3B after 24 hours of wortmannin treatment
was also observed upon immunocytochemical analyses in
PC3 cells (Figure 4C). These data confirm that DNMT
stability is mediated by Akt activity and a disruption of
Akt activation decreases DNMT levels in prostate can-
cer cells.
Mahanine treatment disrupts the interaction of pAkt with
DNMT1 and DNMT3B in prostate cancer cells
Others have demonstrated that Akt stabilizes DNMT1
by phosphorylating its Ser 143 residue, and the dephos-
phorylation of this site makes DNMT1 vulnerable to
ubiquitin-proteasomal degradation [28]. Our finding that
the ubiquitination and proteasomal degradation of DNMT1
and DNMT3B increases in the presence of mahanine
prompted us to check whether mahanine interfered
with Akt mediated stabilization of these DNMTs. Upon
immunoprecipitation of DNMT1 from LNCaP cells treated
with mahanine and MG132 to prevent degradation, we
observed a two-fold decline in serine phosphorylation
of DNMT1 in the presence of mahanine, suggesting
that mahanine is involved in modulating the phosphor-
ylation of DNMT1 (Figure 5A). Furthermore, we observed
a decline in the interaction of phospho-Akt with DNMT1
and DNMT3B in the presence of mahanine, indicating
that mahanine treatment disrupts the interaction of
activated Akt with these DNMTs (Figure 5B). These
data indicate that mahanine modulates stabilizing post-
translational modifications, such as serine phosphoryl-
ation, of DNMT1. In addition, the interaction of a
stabilizing kinase Akt with DNMT1 and DNMT3B is
inhibited in the presence of mahanine, suggesting that
the mechanism of degradation of DNMTs by mahanine
could involve Akt inhibition.
Constitutively active Akt (CA-Akt) rescues mahanine
mediated DNMT1 and DNMT3B degradation in BPH1 cells
To determine whether mahanine induced DNMT1 and
DNMT3B degradation occurs via the inhibition of Akt
activation, BPH1 cells were transfected with a constitu-
tively active Akt expression construct (CA-Akt) or empty
vector following which the cells were treated with or
Figure 4 Mahanine down-regulates pAkt levels and PI3K/Akt inhibitor wortmannin reduces DNMT1 and DNMT3B protein levels. A. PC3
and LNCaP cells were treated with mahanine as indicated. The cell lysates were subjected to Western blot analysis for phospho Akt (pAkt), total
Akt. Β-actin was used as a loading control. B. PC3 and LNCaP cells were treated with wortmannin (1 μM) for 24 hours. Cell lysates were subjected
to Western blot analysis to measure DNMT1, DNMT3B, pAkt and total Akt levels. β-actin was used as a loading control. The fold change in
expression of the respective proteins compared to control is indicated below. C. PC3 cells were treated with DMSO or wortmannin (1 μM) for 24
hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in
methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI.
Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or
wortmannin (1 μM) for 24 hours are shown (right panel).
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known to natively express low levels of DNMT1, DNMT3B
and Akt. The presence of CA-Akt expectedly induced
DNMT1 and DNMT3B levels compared to the control
and empty vector transfected. Surprisingly, this induction
was maintained in the presence by mahanine, indicating
that when Akt is constitutively active, mahanine cannot
carry out proteasomal degradation of DNMTs (Figure 5C).
This clearly demonstrates that the degradation of DNMTs
by mahanine stems from its ability to inactivate Akt.
Discussion
The silencing of the RASSF1A gene has been associated
with advanced stages of prostate cancer [22]. Our prior
work demonstrated that mahanine possesses the ability
to restore RASSF1A expression in several different cancer
cell lines, including androgen-responsive LNCaP and
androgen-receptor negative PC3 prostate cancer cells,which have been derived from metastases to the lymph
node and bone, respectively [25]. However, the scope of
that report did not include defining a molecular mech-
anism to explain the re-expression of RASSF1A upon
mahanine treatment, although it did show a decline in
total DNMT activity in the presence of mahanine [25].
Our current work stems from these findings, and in
this report we establish a molecular mechanism for the
inhibition of DNMT signalling by mahanine; further-
more, we delineate the correlation between DNMT and
RASSF1A expression in prostate cancer cells.
Our data demonstrate that the re-expression of RAS
SF1A upon mahanine treatment is a time sensitive event;
while the demethylation of the RASSF1A promoter is
apparent after 24 hours of mahanine treatment, RASSF1A
expression can only be detected after 72 hours of mahanine
treatment. This shows that the partial de-methylation
of the RASSF1A promoter which occurs after 24 hours
Figure 5 Mahanine disrupts the interaction of pAkt with DNMT1 and DNMT3B and constitutively active Akt (CA-Akt) stabilizes their
cellular levels in the presence of mahanine. A. and B. LNCaP cells were treated with MG132 with or without 20 μM mahanine for 24 hours
and the cell homogenates were subjected to co-immunoprecipitation (IP) for DNMT1 or DNMT3B and immunoblotted (IB) for phosphor-serine
(pSer), pAkt, total Akt, DNMT1 and DNMT3B. C. BPH1 cells were transfected with an empty vector or a constitutively active Akt (CA-Akt)
expression vector for 24 hours then were treated with or without mahanine (10 μM) for another 24 hours. Levels of total Akt, pAkt, DNMT1 and
DNMT3B proteins were measured through Western blots. β-actin was used as a loading control. Quantitative estimations of relative levels of
DNMT1 and DNMT3B proteins were determined by densitometric measurements of immunoblots from three independent experiments after
normalization with β-actin. Columns, mean; bars, SEM. *p < 0.05, significantly different from DMSO treated control.
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expression; the promoter region must be demethylated
to a greater extent, which is only achieved approximately
72 hours following mahanine treatment. This suggests that
mahanine could modulate the activities of certain factors
involved in the maintaining the methylation pattern of
the RASSF1A promoter region, which accounts for the
time lag between mahanine treatment and RASSF1A
re-expression. Since DNMT1, DNMT3A and DNMT3B
are known to be involved in de novo methylation and
the maintenance of methylation patterns of genes, we
investigated the levels of expression of all three members
of the DNMT family. Our data clearly indicates that
mahanine treatment causes a decline in the levels of
DNMT1 and DNMT3B, without affecting the levels of
DNMT3A, in both LNCaP and PC3 prostate cancer
cells. Interestingly, the time frame within which mahanine
down-regulates DNMT1 and DNMT3B in LNCaP and
PC3 cells correlates well with the re-expression of
RASSF1A in these cell types, suggesting that mahanine
could mediate RASSF1A re-expression via DNMT inhib-
ition. Furthermore, these results indicate that mahanine
selectively modulates the cellular levels of certain DNMTs,
without ubiquitously down-regulating the levels of all
members of the DNMT family. This data is furthersupported by our findings that the knock-down or
over-expression of either member of the DNMT family is
sufficient to restore or inhibit the expression of RASSF1A
in PC3 or BPH1 cells, respectively; however to a lesser
extent with DNMT3A. Therefore, mahanine selectively
degrades the two DNMTs which appear to most strongly
inhibit RASSF1A expression in PC3 prostate cancer
cells. The ability of mahanine to selectively target DNMT1
and DNMT3B clearly differentiates it from other known
DNMT inhibitors like 5-aza cytidine and 5-aza-2′-deoxy-
citidine, which ubiquitously bind to and irreversibly inhibit
all members of the DNMT family. Therefore, anti-cancer
agents like mahanine which selectively targets DNMT1
and DNMT3B could be beneficial in prostate cancer
therapy.
While mahanine causes degradation of DNMT1 and
DNMT3B by inducing the chymotrypsin-like activity of
the proteasome, it is interesting to note that it does not
potentiate the trypsin- and caspase-like activities of the
proteasome. The decline in these particular enzymatic
activities of the proteasome upon mahanine treatment
could be to compensate for the significant induction of
the chymotrypsin-like activity upon mahanine treatment
and thereby ensure that the overall proteasomal activity
is balanced and cellular homeostasis is undisturbed.
Figure 6 Mahanine restores RASSF1A expression by degrading
DNMTs via Akt. Prostate cancer cells express high levels of
activated Akt, which phosphorylates and stabilizes DNMT1 and
DNMT3B against proteasomal degradation. DNMTs enter the nucleus
and methylate the promoter of RASSF1A gene to silence the
expression of RASSF1A. Treatment of mahanine inhibits PDK1 and
thereby prevents activation of Akt, which in turn compromises the
stability of DNMTs, increases their ubiquitination and induces
proteasomal degradation. In the absence of DNMT1 and DNMT3B,
the RASSF1A promoter is demethylated and its expression is restored
in prostate cancer cells. GF: Growth factor; RTK: Receptor tyrosine
kinase; TFs: Transcription factors; P: Phosphorylated; M: Methylated;
Ub: Ubiquitinated.
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to be highly up-regulated in prostate cancer, which cor-
relates with the high abundance of DNMTs in prostate
cancer cells, as Akt is involved in the stabilization of
DNMT1, and possibly other DNMTs, via site-specific
phosphorylation on Ser/Thr residues. Interestingly, the
degradation of DNMTs by mahanine is dependent on its
ability to inhibit Akt activity; when Akt is constitutively
active mahanine treatment does not result in protea-
somal degradation of DNMT1 and DNMT3B. A recent
report demonstrated that Akt phosphorylates the Ser143
residue of DNMT1 and thereby increases its stability
[28]. However, no such stabilizing phosphorylation events
have been described to date for DNMT3B. Our data
clearly indicates that Akt is involved in stabilizing not only
DNMT1, but also DNMT3B, since constitutively active
Akt renders both DNMTs resistant to proteasomal deg-
radation induced by mahanine. The mechanism by which
Akt imparts increased stability to DNMT3B remains to
be explored. In addition, our immunoprecipitation data
shows that mahanine causes a striking decrease in the
overall serine phosphorylation of DNMT1, suggesting
that mahanine might modulate the phosphorylation
status of DNMT1 on more than one serine residue, via
the inactivation of other Ser/Thr kinases, in addition to
Akt. It will be interesting to further explore specific
phospho-sites involved in imparting stability to DNMT1
and DNMT3B and the kinases responsible for this
phosphorylation.
Conclusions
In summary, the data presented in this report indicates
that mahanine selectively degrades DNMT1 and DNM
T3B via the ubiquitin-proteasomal pathway in a manner
dependent on the inactivation of Akt signaling. The
degradation of DNMT1 and DNMT3B prompts the
demethylation of the promoter of the silenced tumour
suppressor gene RASSF1A, leading to the restoration of
its expression in prostate cancer cells (Figure 6). There-
fore, mahanine could potentially be used in the therapy
of advanced prostate cancer in men when RASSF1A ex-
pression is silenced.
Methods
Mahanine purification, cell culture, and cell transfection
Mahanine was purified from the leaves of Murraya
koenigii as described in our previous published report
[30]. Human prostate cancer cell lines, PC3 and LNCaP
were obtained from American Type Culture Collection
(Manassas, VA). Cells were grown in IMEM (Gibco Life
Technologies, Grand Island, NY) containing 10% fetal
bovine serum (FBS), 2 mM glutamine, 100 u/ml penicil-
lin G sodium, and 100 mg/ml streptomycin sulfate at
37°C and 5% CO2 [30]. BPH1 cells were obtained fromDr. Simon W. Hayward of Vanderbilt University and cul-
tured in the same medium as mentioned above.
PC3 cells were transfected with DNMT shRNAs
(OriGene Technologies Inc., Rockville, MD) and RASS
F1A expression vector [34]. BPH1 cells were transfected
with 1μg/ml of DNMT expression vectors (OriGene) or
constitutively active Akt (CA-Akt) #17-254 (Upstate Bio-
technology, Lake Placid, NY) plasmids using Genjet vII
reagent (Signagen, Gaithersburg, MD). Forty-eight hours
after transfection, cells were harvested for RT-PCR
analyses.
Live and dead cells were determined according to the
manufacturers’ instructions (Cell Viability/Cytotoxicity
Assay kit, Biotium Inc. Hayward, CA)
Western blot analysis
Western blot analysis was performed according to our
earlier published report [35]. In brief, After 24 hours of
mahanine, wortmannin, and MG132 treatment, cellular
protein extracts were prepared from PC3 and LNCaP
cells after various treatments of mahanine, wortmannin,
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on 8% SDS–PAGE and transferred onto nitrocellulose
membranes (Amersham Hybond-ECL), and immunoblot-
ted with primary antibodies (DNMT1 #2788-1, DNMT3A
#3116-1, DNMT3B #2601-1 and poly-Ubiquitin #6686-1
antibodies were purchased from Epitomics, Burlingame,
CA; phosphorylated-Akt S473 #4060 and total Akt #4685
were purchased from Cell Signaling Technologies, Beverly,
MA; β-actin #Sc47778 antibody was purchased from Santa
Cruz Biotechnology, Inc., Santa Cruz, CA; and phospho-
serine #612546 antibody was obtained from BD Biosci-
ences, San Jose, CA), overnight at 4°C. Immunoreactive
protein bands were detected with horseradish peroxidise-
conjugated secondary antibodies (Santa Cruz) and with
enhanced chemiluminescence system (Santa Cruz) accord-
ing to the manufacturer's instructions. Band intensities
(pixel densities) were quantified by ImageJ software
(National Institutes of Health, Bethesda, MD). The pre-
paration of nuclear extracts and immunoprecipitations
were performed according to our previously published
methods [36].
Immunofluorescence staining
Immunofluorescence staining was performed according
to our previously published report [37]. PC3 cells were
plated onto ECL-coated chamber slides and were treated
with mahanine, wortmannin, or DMSO as controls. The
cells were fixed in −20°C methanol, air-dried, and re-
hydrated in PBS. After blocking (0.2% BSA) cells were
incubated with the primary antibodies (DNMT1, DNM
T3A or DNMT3B #Sc376043 from Santa Cruz Biotech-
nology) overnight at 4°C, followed by incubation with the
Alexa Fluor 488 or 594 conjugated secondary antibodies
(Molecular probes/Invitrogen, Carlsbad, CA) for 1 hour.
Slides were washed, counterstained with DAPI or with
propidium iodide, mounted and viewed under a fluores-
cent Olympus BX microscope (Olympus Corp, Tokyo,
Japan). Images were captured at the same magnification
(20X) and then imported into Adobe Photoshop.
RASSF1A promoter methylation assay
The methylation status of RASSF1A promoter (Amplicon
location: 17881–18115) was determined by Methylation
specific primers according to the previously published
protocol [38,39] with some modifications. In brief, PC3
cells were treated with or without mahanine, and the bi-
sulfite modified DNA was isolated using EZ DNA Methy-
lation™ Kit procured from Zymo research (Irvine, CA).
The PCR reaction was conducted with 4μl of bisulfite-
modified DNA with methylated-specific primers for
RASSF1A (forward primer 5’- GGG TTT TGC GAG
AGC GCG -3’, reverse primer 5’- GCT AAC AAA CGC
GAA CCG -3’) at the annealing temperature of 54°C.
For unmethylated RASSF1A (forward primer 5’- GGTTTT GTG AGA GTG TGT TTA G -3’, reverse primer 5’-
CAC TAA CAA ACA CAA ACC AAA C -3’) annealing
temperature was 47.5°C. After amplification, PCR prod-
ucts were separated on agarose gel and visualized by
ethidium bromide fluorescence using the Fuji LAS-
1000 Imager.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
RNA was extracted from PC3 and LNCaP cells with TRIzol
solution as suggested by the manufacturer (Invitrogen,
Carlsbad, CA) and genes of interest were amplified using
0.5-1 μg of total RNA using Verso 1-Step RT-PCR kit
purchased from Thermo Scientific (Waltham, MA).
Human-specific primers were designed using the Pri-
mer Quest program and purchased from Integrated
DNA Technologies, Inc (Coralville, IA). The primer se-
quences are: DNMT1 forward primer 5- GTGAGGA
CATGCA GCTTTCA −3, reverse primer 5- TGCTGCCT
TTGATGTAGTCG-3, DNMT3A forward primer 5’-
TGAGAGTG ACACTGCCAAGC-3’, reverse primer 5’-
CAGCAGATGGTG CAGTAGGA-3’; DNMT3B forward
primer 5’-TTTGGCCACCTTCAATAAGC-3’, reverse pri-
mer 5’- GGCAACATC TGAAGCCATTT-3’; GAPDH for-
ward primer 5-CCACCCATGGCAAATT CCATGGCA-3,
reverse primer 5-TCTAGACGGCAGGTCAGGTCCAC
C-3’. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and RASSF1A primer sequences have been previously
published [25]. PCRs were initiated at 47°C for 30 min
then 95°C for 1min followed by 30 cycles of 95°C for 1
min, 1 min annealing temperature, 72°C for 1 min, and
final extension at 72°C for 3 min. After amplification,
PCR products were separated on 1.5% agarose gels and
visualized by ethidium bromide fluorescence using the
Fuji LAS-1000 Imager.
Statistical analyses
All data were derived from at least three independent
experiments and statistical analyses were conducted by
using one-way analysis of variance (ANOVA) followed
by the Dunnett’s post-test with an assigned confidence
interval of 95%. Values were presented as means ± SEM.
p-value < 0.05 was considered significant.
Additional files
Additional file 1: Figure S1. Mahanine demethylates RASSF1A
promoter (A) LNCaP cells were treated with 10 μM mahanine for 3 days.
Methylation-specific PCR was performed to detect the methylated (M)
and un-methylated (UM) status of RASSF1A promoter. (B) BPH1 cells were
transfected with DNMT1, DNMT3A and DNMT3B following which the
expression levels of the respective DNMTs were assessed by Western
blotting.
Additional file 2: Figure S2. Mahanine selectively alters DNMT1 and
DNMT3B but not DNMT3A. (A) DNMT1, DNMT3A and DNMT3B expression
was examined by immunofluorescent staining after 24 hours of treatment
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http://www.molecular-cancer.com/content/12/1/99with DMSO or mahanine (10 μM). (B) BPH1 cells were transfected with
DNMT1, DNMT3A and DNMT3B and treated with mahanine (10 μM) for
48 hours following which the expression levels of the respective DNMTs
were assessed by Western blotting.
Additional file 3: Figure S3. Mahanine does not induce caspase
activity. (A) Live and dead staining of LNCaP (upper panel) and PC3
(lower panel) cells cultured for 24 hours with or without mahanine at the
indicated doses. The live cells stained with calcein AM appeared green
and the dead cells stained with EthD-III appeared red. (B) Bright field
images of LNCaP and PC3 cells treated with the indicated dose of
mahanine for 24 hours.
Additional file 4: Figure S4. Mahanine does not induce trypsin-like or
caspase-like proteasomal activity. (A) LNCaP cells were treated with
DMSO (as control) or the indicated doses of mahanine for 24 hours and
caspase-3/7 activities were measured in cell lysates using fluorescence
assay kits. Data are representative of four independent experiments.
Columns represents mean, error bars represent SEM. (B) Chymotrypsin-
like and caspase-like proteasomal activities were assayed subsequent to
incubation with mahanine (10 μM) with or without MG132 (5 μM) for 24
hours. Data are representative of four independent experiments.
Columns, mean; bars, SEM. *p < 0.05, significantly different from control.
(C) PC3 cells were treated with DMSO or mahanine (10 μM) for 24h and
subjected to Western blot analysis for ubiquitination.
Additional file 5: Figure S5. Mahanine decreased cell growth. LNCaP
and PC3 cells were treated with indicated doses of mahanine for 24-48
hours following which cell viability was assessed by MTT assay.
Additional file 6: Figure S6. Akt inhibitor CCT128930 reduces DNMT1
and DNMT3B protein levels. PC3 and LNCaP cells were treated with
CCT128930 (10 μM) for 24 hours. Cell lysates were subjected to Western
blot analysis to measure DNMT1, DNMT3B and pGSK levels.
β-actin was used as a loading control.
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